4/A//SEC Filing
Wirk Shaheen 4/A
Accession 0001415889-25-011857
CIK 0001346830other
Filed
May 1, 8:00 PM ET
Accepted
May 2, 6:12 PM ET
Size
7.9 KB
Accession
0001415889-25-011857
Insider Transaction Report
Form 4/AAmended
Wirk Shaheen
Director
Transactions
- Award
Common Stock
2025-04-15+176,030→ 176,030 total(indirect: By LLC) - Award
Common Stock
2025-04-15+263,164→ 263,164 total(indirect: By LLC)
Footnotes (5)
- [F1]The initial Form 4 inadvertently listed an incorrect transaction code.
- [F2]Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the "Merger"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc.
- [F3]Received in exchange for 1,312,508 shares of Series B Preferred Stock of Legacy Tvardi pursuant to Merger Agreement.
- [F4]The Reporting Person is a Managing Manager of the Palkon Holdings LLC and Palkon TT Holdings LLC (the "Palkon entities"). The Reporting Person may be deemed to share the power to direct the disposition and vote of the shares held by the Palkon entities, but disclaims beneficial ownership, except to any pecuniary interests therein.
- [F5]Received in exchange for 1,962,199 shares of Series B Preferred Stock of Legacy Tvardi pursuant to Merger Agreement.
Documents
Issuer
Tvardi Therapeutics, Inc.
CIK 0001346830
Entity typeother
Related Parties
1- filerCIK 0002050227
Filing Metadata
- Form type
- 4/A
- Filed
- May 1, 8:00 PM ET
- Accepted
- May 2, 6:12 PM ET
- Size
- 7.9 KB